KHIPA-AMED Healthcare R&D Cooperation
- SEOUL, South Korea – The Korea Health Industry Growth Institute (KHIDI) and the Japan Agency for Medical Research and Development (AMED) have formalized a collaborative partnership aimed at...
- AMED, established in 2015, serves as Japan's central hub for managing health research and development.
- KHIDI has actively engaged with AMED since it's inception, fostering international collaboration in health research.
Korea, Japan Strengthen Health Research Ties with New Agreement
Table of Contents
- Korea, Japan Strengthen Health Research Ties with New Agreement
- Building on a Decade of Cooperation
- joint Symposiums Led to Formal Agreement
- Elevating Korea’s Global Health Status
- Key Areas of Cooperation
- participation in the ASPIRE Program
- Leadership Perspectives
- Korea-Japan Research Partnership: A New Era in Health Collaboration
- What is the Korea-Japan Health Research Agreement?
- What is AMED?
- How did this partnership come about?
- What are the Key Areas of Cooperation?
- What is the ASPIRE Program?
- How Does this Agreement benefit Korea?
- What do Leaders Say About This Agreement?
SEOUL, South Korea – The Korea Health Industry Growth Institute (KHIDI) and the Japan Agency for Medical Research and Development (AMED) have formalized a collaborative partnership aimed at bolstering health research initiatives.The memorandum of cooperation (MOC) was signed March 28, solidifying a commitment to joint projects and expanded researcher exchanges.
Building on a Decade of Cooperation
AMED, established in 2015, serves as Japan’s central hub for managing health research and development. It consolidates efforts previously spread across multiple ministries, including Education, Health, Welfare, and Economic Industry, streamlining the promotion of goverment-led R&D projects.
KHIDI has actively engaged with AMED since it’s inception, fostering international collaboration in health research. The recent MOC builds upon a prior agreement signed March 25,marking the 10th anniversary of AMED’s establishment.
joint Symposiums Led to Formal Agreement
The partnership gained momentum through annual Korea-Japan Joint Symposiums. Discussions between Cha Soon-do, director of KHIDI, and Yoshina Nao Mishima, chairman of AMED, led to a consensus on strengthening research collaboration. An agreement to sign the MOC was reached at a symposium held in Korea, culminating in the formal signing.
Elevating Korea’s Global Health Status
KHIDI’s agreement with AMED positions it as the first specialized institution in Korea to partner with the Japanese agency. This also establishes KHIDI as a partner with three major global health research institutions: the U.S. national Institutes of Health (NIH), the UK Medical Research Council (MRC), and AMED.
Key Areas of Cooperation
The MOC outlines several key areas for collaboration, including:
- Promoting joint research projects
- Expanding discussions through seminars and workshops
- Facilitating researcher exchanges
participation in the ASPIRE Program
As part of the agreement, Korea will participate in AMED’s ASPIRE program.This initiative provides funding for large-scale joint research projects in leading scientific fields, fostering collaboration with countries possessing advanced technological capabilities. Currently, 11 countries are involved, including the United States, the United Kingdom, germany, Switzerland, and members of the European Union.
Participation in ASPIRE is expected to enhance practical cooperation, leading to the discovery of new joint projects, expanded researcher networks, and increased researcher exchanges between Korea and Japan.
Leadership Perspectives
Cha Soon-do, director of KHIDI, emphasized the importance of the agreement. “This MOC is particularly meaningful as it fulfills a promise made between the directors of both organizations before the end of Chairman Mishima’s term,” Cha said. he added that KHIDI will support active collaboration between Korean and Japanese researchers and will continue to engage with AMED’s incoming president.
Korea-Japan Research Partnership: A New Era in Health Collaboration
This article explores the recent agreement between the Korea health industry Growth Institute (KHIDI) and the Japan Agency for Medical Research and Progress (AMED), focusing on their collaborative efforts too boost health research. We’ll delve into the background, key areas of cooperation, and the importance of this partnership for Korea and Japan.
What is the Korea-Japan Health Research Agreement?
The Korea Health industry Growth Institute (KHIDI) and the Japan Agency for Medical Research and Development (AMED) have formalized a collaborative partnership through a memorandum of cooperation (MOC). This agreement, signed on March 28, aims to strengthen health research initiatives between the two countries. It signifies a commitment to joint projects and researcher exchanges.
What is AMED?
AMED, established in 2015, serves as Japan’s central hub for managing health research and development. It consolidates efforts previously dispersed across multiple ministries,streamlining the promotion of goverment-led R&D projects in the health sector.
How did this partnership come about?
The collaboration between KHIDI and AMED has been evolving as AMED’s inception. The recent MOC builds on a prior agreement. The partnership gained momentum through annual Korea-Japan Joint Symposiums, with discussions between KHIDI’s director, Cha Soon-do, and AMED’s chairman, Yoshina Nao Mishima, leading to the formal agreement. The formal signing was the culmination of these discussions at a symposium held in Korea.
What are the Key Areas of Cooperation?
the MOC highlights several key areas for collaboration:
- Joint Research Projects: promoting collaborative research efforts between Korean and Japanese researchers.
- Seminars and Workshops: Expanding discussions through seminars and workshops.
- Researcher Exchanges: Facilitating the exchange of researchers to foster knowledge sharing and collaboration.
What is the ASPIRE Program?
The agreement includes Korea’s participation in AMED’s ASPIRE program. ASPIRE provides funding for large-scale joint research projects in leading scientific fields. Currently, 11 countries are involved in this program, including the united States, the United Kingdom, germany, Switzerland, and members of the European Union. Participation is expected to enhance practical cooperation, leading to new joint projects, expanded researcher networks, and an increase in researcher exchanges.
How Does this Agreement benefit Korea?
The agreement elevates Korea’s global health status in several ways. specifically, it:
- First Partnership: Positions KHIDI as the first specialized institution in Korea to partner with AMED.
- global Network: Establishes KHIDI as a partner with three major global health research institutions: the US National Institutes of Health (NIH), the UK Medical Research Council (MRC), and AMED.
- Access to Resources: Provides access to the ASPIRE program,facilitating funding for joint research projects.
comparison of Key Research Partners
The table below summarizes the key partnerships KHIDI now has:
| Partner | Country | Primary Function |
|---|---|---|
| NIH | United States | National Institutes of Health - biomedical and public health research |
| MRC | United Kingdom | Medical Research council – funding for medical research |
| AMED | Japan | Agency for Medical Research and Development – supporting health research initiatives |
What do Leaders Say About This Agreement?
Cha Soon-do, director of KHIDI, emphasized the significance of the agreement. he highlighted that it fulfills a commitment made between the directors of both organizations and that KHIDI will actively support collaboration between Korean and japanese researchers, and will continue to engage with AMED’s incoming president.